Continuous subcutaneous hydrocortisone infusion in pediatric primary adrenal insufficiency: a cohort study
CSHI offers a promising therapeutic alternative for children with PAI who are poorly controlled on oral therapy. It provides more physiological cortisol delivery, improves hormonal control, and appears safe during long-term pediatric use. Larger prospective studies are needed to confirm these findings and evaluate quality-of-life outcomes.
Authors
- Mohammed Cherif Bouyacoub
- Abd El Kader Ait Tayeb
- Khadidja Fouatih (ORCID: https://orcid.org/0009-0009-8794-4138)
- C. Bouvattier
- Séverine Trabado (ORCID: https://orcid.org/0000-0002-1925-1999)
- Jérôme Bouligand (ORCID: https://orcid.org/0000-0002-8691-9469)
- A. Rothenbuhler
- A Ben Yahia
- Lilia Laddada
- Lambert Anne-Sophie
- Tristan Verdelet
- Trouvin Marie-Agathe
- Agnès Linglart
- LECOQ Anne-Lise
- Kenneth CHAPPELL
- Hazar HAIDAR
- Maureen LOPEZ
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre d'Épidémiologie sur les Causes Médicales de Décès (FR)
- Bicêtre Hospital (FR)
Publication Details
- Journal
- Endocrine Connections
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1530/ec-25-0696
- Primary Topic
- Sexual Differentiation and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00